Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A1EWVY8
Tue, 17.06.2025
Formycon AG
Press Release // June 17, 2025
Formycon plans public corporate bond issuance to support next growth phase within attractive Biosimilar markets
Unsecured bond 2025/2029 with a target volume of EUR 50 million and variable interest rate
Proceeds will support the targeted development of biosimilar product portfolio and the execution of the next grow [ … ]
Tue, 17.06.2025
Formycon AG
Disclosure of Inside Information Pursuant to Article 17 of Regulation (EU) No. 596/2014
NOT FOR DISTRIBUTION, PUBLICATION OR TRANSMISSION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR PUBLICATION MAY BE UNLAWFUL. FURTHER RESTRICTIONS APPLY. PLEASE [ … ]
Thu, 05.06.2025
Formycon AG
Press Release // June 5, 2025
Lucentis® biosimilar FYB201/Ranivisio® (ranibizumab) approved in Brazil
Raniviso® becomes first approved Lucentis® biosimilar in Brazil
Commercialization partnership established with Brazilian pharmaceutical company Biomm
Product launch in Brazil expected in Q4 2025, kicking off the commercial rollout of FYB201 [ … ]
Tue, 27.05.2025
Formycon AG
Press Release // May 27, 2025
Formycon and Fresenius Kabi announce the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar, in Canada
FYB202/Otulfi™ is now commercially available in Canada in both subcutaneous and intravenous formulations
Launch expands market presence beyond the U.S. and Europe, offering broader treatment [ … ]
Mon, 19.05.2025
Formycon AG
Press Release // May 19, 2025
Formycon and Fresenius Kabi announce FDA Approval of Interchangeability for FYB202/Otulfi® (ustekinumab-aauz)
Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, Prime Standard, “Formycon”) and its commercialization partner Fresenius Kabi announce today that the U.S. Food and Drug Administration (FDA) designated F [ … ]
Mon, 12.05.2025
Formycon AG
Press Release // May 12, 2025
Formycon reports strong operational performance and financial results for first quarter of 2025
Strong operational start to the year with market approvals for FYB203 (Aflibercept) in Europe and the United Kingdom as well as new commercialization partnerships with Teva and Lotus
Encouraging market launch of FYB202/Ot [ … ]
Wed, 07.05.2025
Formycon AG
Presse Release // May 7, 2025Formycon invites to conference call on the results of the first quarter of 2025 and announces participation in international investor conferences
Planegg-Martinsried, Germany – Formycon AG (FSB: FYB, Prime Standard, „Formycon“) plans to publish its results for the first quarter of 2025 on May 12, 2025. The Management [ … ]
Thu, 27.03.2025
Formycon AG
Press Release // March 27, 2025
Formycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position
Group revenue exceeds forecast with €69.7 million (guidance: €55.0 million to €65.0 million)
Group EBITDA at €-13.7 million also better than expected (guidance: €-25.0 mil [ … ]
Mon, 24.03.2025
Formycon AG
Press Release // March 24, 2025
Formycon invites to conference call on the results of the financial year 2024 and announces participation in international investor conferences in the 2nd quarter of 2025
Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) today announced details of the conference call for the release of the fisca [ … ]
Mon, 03.03.2025
Formycon AG
Press Release // March 3, 2025
FYB202/Otulfi ® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union
FYB202/Otulfi ® is now commercially available in both subcutaneous and intravenous formulations in the United States and the European Union
Patient transition to Otulfi® supported by comparable effic [ … ]